tiprankstipranks
Trending News
More News >
Summit Therapeutics (SMMT)
NASDAQ:SMMT
US Market

Summit Therapeutics (SMMT) Income Statement

Compare
1,835 Followers

Summit Therapeutics Income Statement

Last quarter (Q3 2025), Summit Therapeutics's total revenue was £0.00, a decrease of ― from the same quarter last year. In Q3, Summit Therapeutics's net income was £-231.79M. See Summit Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
£ 0.00£ 0.00£ 704.29K£ 1.81M£ 860.00K
Gross Profit
£ -15.01M£ -2.05M£ -1.81M£ 1.81M£ 860.00K
Operating Expenses
£ 211.30M£ 87.69M£ 64.28M£ 88.00M£ 53.19M
Depreciation and Amortization
£ 17.15M£ 155.32K£ 1.26M£ 2.46M£ 2.00M
EBITDA
£ -212.85M£ -69.45M£ -73.12M£ -85.91M£ -50.65M
Operating Income
£ 313.00K£ -89.74M£ -59.63M£ -86.19M£ -53.19M
Other Income/Expenses
£ -221.63M£ -526.14M£ -6.69M£ -2.42M£ 206.94K
Pretax Income
£ -221.31M£ -615.87M£ -78.78M£ -88.60M£ -52.91M
Net Income
£ -221.31M£ -614.93M£ -78.78M£ -88.60M£ -52.70M
Per Share Metrics
Basic EPS
£ -0.31£ -0.99£ -0.41£ -0.96£ -0.76
Diluted EPS
£ -0.31£ -0.99£ -0.38£ -0.96£ -0.76
Weighted Average Shares Outstanding
718.54M 619.65M 193.34M 92.24M 69.52M
Weighted Average Shares Outstanding (Diluted)
718.54M 619.65M 193.34M 92.24M 69.52M
Currency in GBP

Summit Therapeutics Earnings and Revenue History